Provides Greater Value than STAAR Could Achieve on a Standalone Basis in the Foreseeable Future and is the Best Path Forward for STAAR Stockholders Files Definitive Proxy Materials and Mails Letter to STAAR Stockholders Encourages Stockholders to Vote “FOR” the Value Maximizing Alcon Merger Today LAKE FOREST, Calif. / Sep 16, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with... Read More

LAKE FOREST, Calif. / Sep 02, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses (EVO ICL™) for vision correction, issued the following statement: “The merger with Alcon provides STAAR stockholders with compelling, premium cash value, including a 51% premium to the closing price of STAAR common stock on August 4, 2025 (the day... Read More

LAKE FOREST, Calif. / Aug 06, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales... Read More

LAKE FOREST, Calif. / Jul 31, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30... Read More

LAKE FOREST, Calif. / Jun 25, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR’s CFO from 2007-2013... Read More

LAKE FOREST, Calif. / May 22, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2025 Virtual Ophthalmology Forum Date: Tuesday, May 27, 2025 Format: Meetings and Webcast Fireside Chat Webcast: 2:00 PM... Read More

LAKE FOREST, Calif. / May 16, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. “Our decision to initiate a share... Read More

China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern LAKE FOREST, Calif. / May 07, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported... Read More

LAKE FOREST, Calif. / Apr 24, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company’s Board from 2014-2022, as a director, effective April 24, 2025. The... Read More

LAKE FOREST, Calif. / Apr 23, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m.... Read More

Warren Foust Named President and Chief Operating Officer Magda Michna, PhD Appointed Chief Development Officer Deborah Andrews, STAAR’s Chief Financial Officer from 2017- 2020, to serve as Interim Chief Financial Officer Patrick F. Williams Steps Down as Chief Financial Officer Keith Holliday Retires as Chief Technology Officer LAKE FOREST, Calif. / Mar 17, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the... Read More

Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair LAKE FOREST, Calif. / Feb 26, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of... Read More

Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024 Introduces Outlook for Fiscal 2025 Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern LAKE FOREST, Calif. / Feb 11, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO... Read More

LAKE FOREST, Calif. / Jan 13, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close. “Our industry-leading EVO ICL... Read More

LAKE FOREST, Calif. / Nov 25, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors and a fireside chat at the 4 th Annual BTIG Ophthalmology Day. Event: 4th Annual BTIG Ophthalmology Day... Read More

LAKE FOREST, Calif. / Nov 13, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with STAAR Management at the upcoming Stephens Annual Investment Conference, which will be held in Nashville,... Read More

Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions Americas Up 14%, EMEA Up 12% and APAC Up 9% Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity LAKE FOREST, Calif. / Oct 30, 2024 / Business Wire / The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior... Read More

Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions Americas Up 14%, EMEA Up 12% and APAC Up 9% Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity LAKE FOREST, Calif. / Oct 30, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia,... Read More

LAKE FOREST, Calif. / Oct 23, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close. Event: STAAR Surgical 3Q 2024... Read More

State-of-the-Art Facility Elevates Ophthalmic Education, Empowering Surgeons and Practitioners to Lead the Future of Vision Correction Myopia in the U.S. has doubled over the past three decades with an expected prevalence of 58.4% by 2050 1 EVO ICL TM units, a proxy for procedures, grew by 25% in the U.S. in 1H 2024 2 More than 700 U.S. surgeons are now certified by STAAR Surgical to perform EVO ICL 2 LAKE FOREST, Calif. /... Read More

Record Quarterly Net Sales of $99.0 Million; $100.4 Million in Constant Currency Raises Fiscal 2024 Net Sales and Adjusted EBITDA Outlook LAKE FOREST, Calif. / Aug 07, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the second... Read More

LAKE FOREST, Calif. / Jul 31, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024, after the market close. Event: STAAR Surgical 2Q 2024... Read More

LAKE FOREST, Calif. / Jul 30, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Canaccord Genuity 44th Annual Growth... Read More

LAKE FOREST, Calif. / Jun 05, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45 th Annual Global... Read More

Agreement is Largest Commitment to EVO ICL™ in the U.S. LAKE FOREST, Calif. / May 07, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announces another... Read More

EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA LAKE FOREST, Calif. / May 07, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and... Read More

New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth LAKE FOREST, Calif. / May 01, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia,... Read More

LAKE FOREST, Calif. / Apr 29, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close. STAAR will host a conference call and... Read More

Total Net Sales in Excess of $77 Million Including Record Quarterly U.S. ICL Sales of $5 Million LAKE FOREST, Calif. / Apr 04, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are... Read More

Scientific content at ASCRS related to EVO ICL™ doubles with 44 posters and presentations STAAR is leading a comprehensive clinical education program including a lunch symposium, multiple in-booth and offsite events, as well as online through the launch of STAAR University EVO ICL advocate, Will Levis, Tennessee Titans... Read More

LAKE FOREST, Calif. / Mar 18, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally. 1 “We extend... Read More

LAKE FOREST, Calif. / Mar 12, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President... Read More

LAKE FOREST, Calif. / Mar 06, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences: Oppenheimer Healthcare MedTech & Services Conference, Tuesday, March 12 Sidoti... Read More

Generates Double-Digit Sales Growth and Continuing Profitability ICL Sales Up 22% in Fourth Quarter and 18% in Fiscal 2023 Affirms Sales Outlook for Fiscal 2024 LAKE FOREST, Calif. / Feb 26, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial... Read More

LAKE FOREST, Calif. / Feb 19, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close. STAAR will host a conference... Read More

LAKE FOREST, Calif. / Jan 23, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, and SharpeVision, a premier ophthalmology group with clinics in Seattle, Chicago and... Read More

Net Sales Up 19% for Fourth Quarter and 13% for Fiscal 2023 1 ICL Sales Up 22% for Fourth Quarter and 18% for Fiscal 2023 Provides Fiscal 2024 Sales Outlook of $335 Million to $340 Million LAKE FOREST, Calif. / Jan 08, 2024 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer ® Lenses (EVO ICL) for myopia, astigmatism and presbyopia,... Read More

LAKE FOREST, Calif. / Dec 04, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. “We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an... Read More

LAKE FOREST, Calif. / Nov 15, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced that management will participate in the Stephens Annual Investment Conference on Thursday, November 16, 2023. Management will participate in a Fireside Chat on Thursday,... Read More

Net Sales of $80.3 Million; ICL Sales of $81.1 Million Up 13% Y/Y 23rd Consecutive Quarter of Double-Digit ICL Sales Growth 1 LAKE FOREST, Calif. / Nov 01, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended... Read More

LAKE FOREST, Calif. / Oct 18, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the third quarter ended September 29, 2023 on Wednesday, November 1, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, November 1 at 4:30 p.m. Eastern /... Read More

ICL Corrects/Reduces Refractive Error for Glasses and Contact Lens Wearers 99.4% of Patients Surveyed Would Have ICL Procedure Again 1 LAKE FOREST, Calif. / Oct 17, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, is celebrating the 30 th anniversary of its proprietary Implantable Collamer® Lens (ICL). The first ICLs were implanted... Read More

LAKE FOREST, Calif. , Oct. 10, 2023 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, is proud to announce a partnership with renowned actor and comedian, Jimmy O. Yang . This partnership brings together EVO Implantable Collamer ® Lenses... Read More

LAKE FOREST, Calif. / Sep 14, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, will host Vision 2026, the Company’s investor day, at the Nasdaq MarketSite in Times Square today. To honor the occasion and celebrate the 40th anniversary of being listed as a public company, Tom Frinzi, Chair of the Board and CEO, along with the... Read More

LAKE FOREST, Calif. / Sep 07, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will host an in-person Investor Day on Thursday, September 14, 2023, beginning at 8:00 a.m. Eastern Time in New York City. The “Vision 2026” Investor Day will highlight key company initiatives and projects including, several next... Read More

NEW YORK , Aug. 17, 2023 /PRNewswire/ -- Dolby Laboratories Inc. (NYSE:DLB) will replace Staar Surgical Co. (NASD:STAA) in the S&P MidCap 400 and Staar Surgical will replace Urstadt Biddle Properties Inc. (NYSE:UBA) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, August 22 . S&P 500 constituent Regency Centers Corp. (NASD: REG) will acquire Urstadt Biddle Properties in a transaction expected to... Read More

LAKE FOREST, Calif. / Aug 09, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced its partnership with Will Levis, quarterback for the Tennessee Titans of the National Football League (NFL). This partnership will raise... Read More

LAKE FOREST, Calif. / Aug 07, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that management will participate in several upcoming investor conferences. STAAR management will participate in the following investor conferences: Canaccord Genuity Annual Growth Conference, Wednesday, August 9. Management Presentation... Read More

Record ICL Sales of $93.1 Million Up 19% Y/Y LAKE FOREST, Calif. / Aug 02, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Overview Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products... Read More

LAKE FOREST, Calif. / Jul 19, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second quarter ended June 30, 2023 on Wednesday, August 2, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, August 2 at 4:30 p.m. Eastern / 1:30 p.m.... Read More

LAKE FOREST, Calif. / May 04, 2023 / Business Wire / EVO ICL, the vision correction procedure that works in harmony with your natural eye, provides sharp, clear vision day or night and does not cause contact lens induced dry eye or dry eye syndrome, announced today sponsorship of the Jonas Brothers’ The Tour in North America, which begins August 12. Collaboration with the group will also include a new EVO advertising... Read More

Q1 2023 Net Sales of $73.5 Million; ICL Sales of $70.6 Million Up 20% Y/Y Fiscal 2023 Net Sales Outlook Raised to $348 Million; ICL Sales to $345 Million Up 28% Y/Y LAKE FOREST, Calif. / May 03, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the first quarter ended March 31, 2023. First... Read More

LAKE FOREST, Calif. / Apr 19, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter ended March 31, 2023 on Wednesday, May 3, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, May 3 at 4:30 p.m. Eastern / 1:30 p.m. Pacific... Read More

New Positions Demonstrate Increased Commitment and Focus on Continued Industry Leading Growth LAKE FOREST, Calif. / Mar 29, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced Warren Foust has been named Chief Operating Officer and Magda Michna, Ph.D., has been named Chief Clinical, Regulatory and Medical Affairs... Read More

LAKE FOREST, Calif. / Feb 21, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the fourth quarter and fiscal year ended December 30, 2022. Fourth Quarter 2022 Overview Net Sales of $64.0 Million Up 9% and Constant Currency Net Sales of $67.9 Million Up 15% from Prior Year Quarter ICL Sales of... Read More

LAKE FOREST, Calif. / Feb 07, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended December 30, 2022, on Tuesday, February 21, 2023 after the market close. STAAR will host a conference call and webcast on... Read More

Cobra Kai Star Peyton List is the Latest Celebrity Bringing Life Into Focus with EVO ICL Lenses STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses, today announced a partnership with actress and beauty entrepreneur, Peyton List, to further its mission of bringing EVO... Read More

ICL Unit Growth of 20% Y/Y for the Fourth Quarter and 33% Y/Y for Fiscal 2022 U.S. ICL Units Up 109% Y/Y for the Fourth Quarter 2022 Outlook for Approximately 25% Y/Y ICL Sales Growth for Fiscal 2023 STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported preliminary sales for the fourth quarter and fiscal year ended December 30, 2022.... Read More